ELEVIDYS Archives - PharmaDeviceNews

Sarepta’s sirolimus gambit: Can enhanced immunosuppression rescue ELEVIDYS for non-ambulatory Duchenne patients?

By Pallavi Madhiraju on March 17, 2026 Pharma & Biotech

Sarepta’s ELEVIDYS Cohort 8 targets non-ambulatory Duchenne patients with a sirolimus regimen. What the trial design reveals about the path to label restoration.

Can Sarepta’s ELEVIDYS redefine Duchenne therapy? Inside the 3-year EMBARK data

By Pallavi Madhiraju on January 26, 2026 Pharma & Biotech

Sarepta’s gene therapy ELEVIDYS shows 3-year durability in Duchenne muscular dystrophy. Find out what it means for patients, payers, and global rollout.

Can ELEVIDYS meet its promise? Sarepta’s pivotal Duchenne gene therapy trial nears major milestone

By Pallavi Madhiraju on January 24, 2026 Pharma & Biotech

Sarepta’s EMBARK 3-year readout could clarify ELEVIDYS’ long-term role in Duchenne care. Find out what’s at stake in this pivotal gene therapy trial.